CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Itolizumab IV infusionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug299 BMS-986256 Wiki 1.00
drug1492 Milk of magnesia Wiki 1.00
drug341 Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications

Randomized, Parallel Group, Active Controlled Trial

NCT04475588 Acute Respiratory Distress Syndrome Cytokine Release Syndrome Covid19 Drug: Itolizumab IV infusion Drug: Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: 1-month mortality is defined as the ratio of patients who will live after 1 month from study start out of those registered at baseline

Measure: One-month mortality rate between the two arms

Time: One-month

Secondary Outcomes

Description: Baseline, during treatment, One month

Measure: Biomarkers (IL-6, TNF-a, IL1, IL17, etc…)

Time: One Month

Description: Baseline, during treatment (Before every dose and 12 h post dose) up to 1 month

Measure: Lymphocyte count

Time: One Month

Description: Baseline, during treatment (Before every dose and 12 h post dose) up to 1 month

Measure: CRP (C-reactive protein) level

Time: One Month

Description: Baseline, during treatment (Before every dose and 12 h post dose) up to 1 month

Measure: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)

Time: One Month

Description: At baseline, after seven days and if clinically indicated (up to 1 month)

Measure: Radiological response

Time: one month

Description: from baseline up to patients discharge (up to 1 month)

Measure: Duration of hospitalization

Time: One Month

Description: up to 1 month

Measure: Remission of respiratory symptoms

Time: One Month


No related HPO nodes (Using clinical trials)